BCAX Insider Trading Activity and SEC Form 4 Filings
BCAX insider trading summary
Over the past 12 months, insiders at Bicara Therapeutics Inc. (BCAX) reported 45 sales worth $7.8M by 4 insiders and 5 open-market purchases worth $24.0M by 5 insiders on SEC Form 4. Net insider buying was $16.2M.
Latest BCAX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 10, 2026 | Ivan Hyep | Chief Financial Officer | Sell | $350K (12,500 @ $27.97) |
| Aug 10, 2026 | Claire Mazumdar | Chief Executive Officer | Sell | $280K (10,000 @ $27.98) |
| Aug 10, 2026 | Ryan Cohlhepp | President and COO | Sell | $525K (18,750 @ $27.98) |
| Jul 10, 2026 | Claire Mazumdar | Chief Executive Officer | Sell | $831 (28 @ $29.68) |
| Jul 10, 2026 | Claire Mazumdar | Chief Executive Officer | Sell | $283K (9,972 @ $28.42) |
| Jul 9, 2026 | Ryan Cohlhepp | President and COO | Sell | $16K (536 @ $29.00) |
| Jul 8, 2026 | Ivan Hyep | Chief Financial Officer | Sell | $651K (22,757 @ $28.60) |
| Jul 8, 2026 | Ryan Cohlhepp | President and COO | Sell | $33K (1,075 @ $30.35) |
| Jul 8, 2026 | Ryan Cohlhepp | President and COO | Sell | $657K (22,833 @ $28.76) |
| Jul 8, 2026 | Ivan Hyep | Chief Financial Officer | Sell | $25K (830 @ $30.31) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.